Ideal Cures 'building business' with PE investment

By Melissa Fassbender

- Last updated on GMT

Ideal Cures 'building businesses' with PE investment

Related tags Corporation

Idea Cures has announced an investment from the global private equity firm, TA Associates, as it aims to grow its manufacturing business.

Ideal Cures has three manufacturing plants located in Vasai, Jammu, and Khambat and two R&D facilities in Mumbai and Vasai. The coating and excipient provider also has another plant under construction​ in Sikkim.

Kamlesh Oza PhD, President, Global Business Development at Ideal Cures, told us, “with the advent of TA coming on board customers will be confident of a global, long-term, secure supply chain​.”

With the investment, financial terms of which were not disclosed, Oza said Ideal Cures is building its business and teams.

Additionally, Oza said the company will leverage TA in order to expand its global business, “especially with multinational companies​,” he added. 

Over the years, TA has developed relationships in the healthcare space who are or will be potential customers for Ideal Cures​,” Oza explained. “Further, TA’s corporate development capabilities will provide the financial and operational expertise to help the company expand upon its solutions​.”

(Feature image: iStock/Nastco)

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more